Related Experiment Video
Updated: May 18, 2026
08:01
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
Ancillary approaches to plasminogen activators.
Reza Bavarsad Shahripour1, Andrei V Alexandrov
1Department of Neurology, Joundishapour University of Medical Sciences, Ahvaz, Khuzestan, Iran.
Annals of the New York Academy of Sciences
|September 22, 2012
Summary
Combination therapies, including tissue plasminogen activator (t-PA) with other drugs or methods, show promise for improving acute ischemic stroke treatment by restoring cerebral blood flow.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Pharmacology
Background:
- Acute ischemic stroke results from interrupted cerebral blood flow, often due to thromboembolism.
- Current systemic fibrinolytic therapy is a breakthrough but requires further advancements.
- Improved methods to restore cerebral blood flow are crucial for managing acute ischemic stroke.
Purpose of the Study:
- To review ongoing clinical trials and safety of combinatory treatments for acute ischemic stroke.
- To explore the potential of combination pharmacotherapy in enhancing thrombolytic treatment.
- To evaluate novel pharmacological and non-pharmacological approaches for stroke management.
Main Methods:
- Review of clinical trials investigating combination therapies for acute ischemic stroke.
- Analysis of treatments combining tissue plasminogen activator (t-PA) with antiplatelets and anticoagulants.
- Evaluation of non-pharmacological interventions such as sonothrombolysis, laser therapy, hypothermia, and blood flow augmentation.
Main Results:
- Combination therapies, including t-PA with antiplatelets/anticoagulants, are under investigation.
- Non-pharmacological methods combined with t-PA aim to amplify thrombolytic effects, promote neuro-recovery, provide cytoprotection, and augment blood flow.
- Ongoing trials are assessing the safety and efficacy of these diverse combinatory treatments.
Conclusions:
- Combination therapy holds significant potential to improve acute ischemic stroke management.
- Integrating pharmacological and non-pharmacological approaches offers promising avenues for restoring cerebral blood flow.
- Further research and clinical trials are essential to establish the safety and effectiveness of these advanced treatments.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...